Search results
Roche’s VABYSMO has successful Q1 sales despite Regeneron and Bayer’s EYLEA HD launch
Pharmaceutical Technology via Yahoo Finance· 1 day agoLast week, Roche released promising first-quarter (Q1) 2024 sales figures for VABYSMO, a vascular...
Story from Associated Retina Consultants: Local group helps macular degeneration patients cope with...
The Arizona Republic· 6 days agoAccording to the Centers for Disease Control and Prevention (CDC), nearly 20 million Americans over ...
EYLEA HD shows promise in long-term clinical trials By Investing.com
Investing.com· 3 days agoHD clinical program during a series of presentations at the Association for Research in Vision and...
Dear Doctor: Can I use over-the-counter eye drops while on medications for macular degeneration?
OregonLive.com· 7 days agoROACH: I am a healthy 67-year-old female being treated with Eylea for wet age-related macular degeneration ...
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024 - Ocular...
Benzinga· 1 day agoOcular Therapeutix, Inc. OCUL "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization ...
...Application for EB-105 - A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) -...
WTNH-TV New Haven· 2 days agoEluminex Biosciences (Eluminex), a privately-held biotechnology company focused on the development...
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 2 days agoAn increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided...
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends - Regeneron Pharmaceuticals...
Benzinga· 2 days agoThe company has several marketed products, including Eylea, approved for wet age-related macular degeneration ...
Kodiak Sciences Inc. (NASDAQ:KOD) Given Average Rating of “Reduce” by Analysts
ETF DAILY NEWS· 1 day agoKodiak Sciences Inc. (NASDAQ:KOD – Get Free Report) has been assigned an average rating of “Reduce” from the seven brokerages that are currently covering the stock, Marketbeat reports. Three ...
Small Business - Austin Daily Herald | Austin Daily Herald
Austin Daily Herald· 1 hour agoFirst quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first
